Clinical Trials of Novel Therapeutic Agents: Why did they fail?
Clinical trials of sepsis have been described as “The Bermuda Triangle of the Biotechnology Industry”, or perhaps more aptly a “black hole” into which large sums of money and resources disappear with no visible return. The unexpected and generally disappointing results of clinical trials for sepsis has been the subject of numerous editorials and critical commentaries [1–5]. Several thousand patients have been enrolled in randomized trials of immunotherapy of severe sepsis; yet, no single agent has demonstrated sufficiently convincing clinical data to warrant licensure as an approved therapeutic agent. It is imperative that we determine the cause(s) of these failures as we continue to attempt to develop adjuvant therapies for this common and potentially lethal condition. These results have prompted investigators to consider a number of critical questions raised by recent failures in sepsis trials.
KeywordsPlacebo Toxicity Catheter Europe Pneumonia
Unable to display preview. Download preview PDF.
- 1.Cross AS, Opal S (1994) Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? J Endotoxin Res 1: 57–69Google Scholar
- 7.McCloskey RV, Straube RC, Sanders C, Smith CR and the CHESS Trial Study Group (1994) Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial period. Ann Intern Med 120: 1–5Google Scholar
- 9.Wenzel R, Bone R, Fein A, et al (1991) Results of a second, double-blind randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis. Antimicrob Agents Chemother 294: 1170 (Abst)Google Scholar
- 11.Wherry J, Wenzel R, Abraham E, et al (1993) A controlled randomized, double-blind clinical trial of a monoclonal antibody to human tumor necrosis factor (TNF MAb) in patients with sepsis syndrome. Chest 105: 35 (Abst)Google Scholar
- 12.Carlet J, Cohen J, Andersson J, et al (1994) INTERSEPT: An international efficacy and safety study of monoclonal antibody to human tumor necrosis factor in patients with the sepsis syndrome. Antimicrob Agents Chemother 7: (Abst B/1)Google Scholar
- 13.Agosti JM, Fisher JC, Opal SM, et al (1994) Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). Antimicrob Agents Chemother 65: (Abst M3)Google Scholar
- 14.Fisher JC, Slotman GS, Opal SM, et al (1994) Initial evaluation of human recombinant Interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 2: 12–21Google Scholar
- 16.Dhainaut JF, Tenaillon A, Le Tulzo Y, et al (1995) Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo- controlled multicenter trial. Crit Care Med (in press)Google Scholar
- 18.Lowry SF (1993) Hormone in cytokine regulation of injury metabolism. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine 1993. Springer-Verlag, Berlin, pp 1–11Google Scholar